Timothy L Arthur, CRNA | |
1423 7th St, Aurora, NE 68818-1141 | |
(402) 694-3171 | |
(402) 694-5024 |
Full Name | Timothy L Arthur |
---|---|
Gender | Male |
Speciality | Nurse Anesthetist, Certified Registered |
Location | 1423 7th St, Aurora, Nebraska |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1750390431 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
367500000X | Nurse Anesthetist, Certified Registered | 100367 (Nebraska) | Primary |
Mailing Address | Practice Location Address |
---|---|
Timothy L Arthur, CRNA 1423 7th St, Aurora, NE 68818-1141 Ph: (402) 694-3171 | Timothy L Arthur, CRNA 1423 7th St, Aurora, NE 68818-1141 Ph: (402) 694-3171 |
News Archive
Valley Pain Consultants, a division of Valley Anesthesiology Consultants, announced the relocation of its Paradise Valley office to 3301 N. Miller Road, Suite 120, Scloottsdale, AZ 85251.
A new study says that children whose parents smoke tend to miss more school than their classmates with non-smoking parents — possibly because of a higher rate of respiratory infections.
The World Health Organization (WHO), in consultation with the government of the United Kingdom, has designated the Liverpool School of Tropical Medicine (LSTM) as a WHO Collaborating Centre for Evidence Synthesis for Infectious and Tropical Diseases.
A single test for women has been shown to aid in predicting which cases of precancerous cervical disease will become more serious, helping with decisions on whether or not surgery is needed, according to a study led by Queen Mary University of London.
Eisai Inc. announced today that its parent company Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Halozyme Therapeutics, Inc. (Headquarters: San Diego, California, President and CEO: Dr. Helen Torley) have signed a clinical collaboration agreement to evaluate Eisai's agent eribulin mesylate (brand name: Halaven, "eribulin") in combination with Halozyme's investigational drug PEGPH20 (PEGylated recombinant human hyaluronidase) in first line HER2-negative metastatic breast cancer.
› Verified 3 days ago